Non-therapeutic risk factors for onset of Tardive Dyskinesia in schizophrenia: A meta-analysis

Movement Disorders

Volumn 24, Issue 16, 2009, Pages 2309-2315

  Tenback, Diederik E ^a,b   Van Harten, Peter N ^a,c   Van Os, Jim ^d,e  

^a Symfora Group Psychiatric Center   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Akathisia; Drug induced; Extrapyramidal tracts; Longitudinal studies; Movement disorder

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; ETHNIC GROUP; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL PATIENT; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SENESCENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

AGE FACTORS; AKATHISIA, DRUG-INDUCED; DATABASES, FACTUAL; HUMANS; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 73949099769     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22707     Document Type: Review

References (35)

1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
2. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66:1130-1133.
3. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrneia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull 2008 [Epub ahead of print].
4. Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS, Kupfer DJ. Coming to terms with the terms of risk. Arch Gen Psychiatry 1997;54:337-343.
5. Koren G, Maltepe C, Navioz Y, Wolpin J. Recall bias of the symptoms of nausea and vomiting of pregnancy. Am J Obstet Gynecol 2004;190:485-488.
6. van Winkel R, Myin-Germeys I, De Hert M, Delespaul P, Peuskens J, van Os J. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved? Acta Psychiatr Scand 2007;116:119-124.
7. Jabben N, van Os J, Janssen I, Versmissen D, Krabbendam L. Cognitive alterations in groups at risk for psychosis: neutral markers of genetic risk or indicators of social disability? Acta Psychiatr Scand 2007;116:253-262.
8. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000;61 (Suppl 4):10-14.
9. Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1990;20:835-842.
10. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 2002;181:135-137.
11. Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006;21:35-42.
12. Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997;171:148-153.
13. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006;83:185-192.
14. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544-556.
15. Annesi I, Moreau T, Lellouch J. Ef.ciency of the logistic regression and Cox proportional hazards models in longitudinal studies. Stat Med 1989;8:1515-1521.
16. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996;53:313-319.
17. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8 (4 Suppl):21S-26S.
18. Gardos G, Perenyi A, Cole JO, Samu I, Kocsis E, Casey DE. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology 1988;1:169-172.
19. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in fist-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003;64:1075-1080.
20. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry 2004;38:445-449.
21. Tenback DE, van Harten PN, Slooff CJ, van Os J. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006;31:1832-1837.
22. van Harten PN, Hoek HW, Matroos GE, van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V. J Clin Psychiatry 2006;67: 1920-1927.
23. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163:1438-1440.
24. McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P. Facial dyskinesia: a 16-year follow-up study. Br J Psychiatry 1991;158:691-696.
25. Inada T, Ohnishi K, Kamisada M, et al. A prospective study of tardive dyskinesia in Japan. Eur Arch Psychiatry Clin Neurosci 1991;240:250-254.
26. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154:523-528.
27. Dean CE, Russell JM, Kuskowski MA, Caligiuri MP, Nugent SM. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol 2004;24:298-304.
28. Dean CE, Kuskowski MA, Caligiuri MP. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J Clin Psychopharmacol 2006;26:560-565.
29. Blanchet PJ, Abdillahi O, Beauvais C, Rompre PH, Lavigne GJ. Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 2004;19:892-896.
30. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999;156:309-311.
31. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
32. Boks MP, Liddle PF, Burgerhof JG, Knegtering R, van den Bosch RJ. Neurological soft signs discriminating mood disorders from first episode schizophrenia. Acta Psychiatr Scand 2004;110:29-35.
33. van Rossum I, Tenback D, van Os J. Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry 2009;9:16.
34. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009;35:549-562.
35. Egan MF, Hyde TM, Bonomo JB, et al. Relative risk of neurological signs in siblings of patients with schizophrenia. Am J Psychiatry 2001;158:1827-1834.